Repurposing of drugs for triple negative breast cancer: an overview

Andrea Spini1,2, Sandra Donnini3, Pan Pantziarka4, Sergio Crispino4,5 and Marina Ziche1

1Department of Medicine, Surgery and Neuroscience, University of Siena, Siena 53100, Italy
2Service de Pharmacologie Médicale, INSERM U1219, University of Bordeaux, Bordeaux 33000, France
3Department of Life Sciences, University of Siena, Siena 53100, Italy
4Anticancer Fund, Strombeek Bever 1853, Belgium
5ASSO, Siena, Italy

Correspondence to: Marina Ziche
Email: marina.ziche@unisi.it

Abstract

Breast cancer (BC) is the most frequent cancer among women in the world and it remains a leading cause of cancer death in women globally. Among BCs, triple negative breast cancer (TNBC) is the most aggressive, and for its histochemical and molecular characteristics is also the one whose therapeutic opportunities are most limited. The REpurposing Drugs in Oncology (ReDO) project investigates the potential use of off patent non-cancer drugs as sources of new cancer therapies. Repurposing of old non-cancer drugs, clinically approved, off patent and with known targets into oncological indications, offers potentially cheaper effective and safe drugs. In line with this project, this article describes a comprehensive overview of preclinical or clinical evidence of drugs included in the ReDO database and/or PubMed for repurposing as anticancer drugs into TNBC therapeutic treatments.

Keywords: triple negative breast cancer, repositioning, non-cancer drug, preclinical studies, clinical studies

Background

Breast cancer (BC) is the most frequent cancer among women in the world. Triple negative breast cancer (TNBC) is a type of BC that does not express oestrogen receptors, progesterone receptors and epidermal growth factor receptors-2/Neu (HER2) and accounts for the 16% of BCs approximately [1, 2]. Due to its lack of response to hormone and targeted therapies, the number of therapeutic opportunities is limited [3, 4]. TNBC patients are difficult to treat, with unfavourable prognosis and are generally administered with the standard chemotherapy. At the moment, novel treatment approaches, such as immunotherapy, as well the repurposing of old drugs currently used for indications other than TNBC, is under investigation. In this context, we have previously reviewed the preclinical and clinical anticancer efficacy and safety of beta blockers in TNBC [5].

Drug repurposing is the application of an old drug to a new disease indication: this holds the promise of rapid clinical impact at a lower cost than de novo drug development [6]. In oncology, where new treatments in the last years are becoming more expensive due to the introduction of innovative therapies such as targeted therapies and immunotherapies,
there is an increased interest at the use of already clinically approved non-cancer drugs, off patent and with known targets, as possible cancer treatments [7]. One study published by Pantziarka et al [8], point the spotlight on this matter building up a project about drug repurposing in the treatment of cancer. The REpurposing Drugs in Oncology (ReDO) project investigates the potential use of licensed non-cancer medications as sources of new cancer strategies. ReDO project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. At present, data of 268 drugs have been included in the REDO database (ReDO_DB) [8].

In line with this project, we searched in PubMed for published preclinical or clinical evidence of anticancer activity for all drugs included in the ReDO_DB for TNBC. Specifically, starting from each drug present in ReDO_DB, we searched in PubMed for published preclinical and clinical evidence of anticancer activity for TNBC. The strings were composed by the name of the drugs and specific keywords related to TNBC.

An additional search string was used to investigate potential clinical evidence about drugs not included in ReDO_DB or references not retrieved in the first search. The string was composed by three blocks concerning keywords related to TNBC, repurposing and study type, respectively. Both strings are provided in the supplementary file (Table S1). Observational or clinical trials for which a TNBC cohort was defined were included. The articles that were not written in English were excluded.

Moreover, clinicaltrials.gov [9] was searched for ongoing or completed clinical studies on drug repurposing and TNBC. All searches were performed on March 2019, and the information extracted were the following: 1) preclinical studies: number of studies per drug and pharmacological activity; 2) clinical studies: study type, country, study period, population studies, exclusion criteria, age, follow up, arms, treatments and outcomes; 3) clinicaltrials.gov: number of studies per drug.

The aim of this paper is to give to clinicians and scientists a comprehensive overview about preclinical and clinical studies, including clinical trials, present in literature on the repurposing of old-licensed drugs for TNBC.

We found 188 preclinical studies references (see Supplementary Material), 18 clinical references [10–26] and 16 references on clinical trials. gov on drug repurposing for TNBC [9].

**Preclinical studies**

Using the PubMed database, we found preclinical evidence on TNBC models (cell lines and xenograft models of TNBC) for 84 out of 268 old drugs (31.3%) present in the ReDO_DB. For 42 of the 84 drugs, only one reference was retrieved (Table S2). Thirteen studies referred to the anti-proliferative, pro-apoptotic and immune-stimulating effects of metformin, thirteen to the cytotoxic and anti-metastatic effects of chloroquine, eleven to the anti-proliferative and anti-invasive effects of simvastatin, eight to the anti-inflammatory and anti-angiogenic effects of acid acetylsalicylic and eight studies to the anti-angiogenic, anti-proliferative and anti-apoptotic effects of zoledronic acid. Main indications for drugs with preclinical evidence of efficacy on TNBC model were various and heterogeneous including epilepsy, analgesia, hypertension, diabetes, insomnia and other.

**Clinical studies**

Table 1 shows all 17 clinical references collected (the article of Spera et al analyses two different retrospective studies on beta blockers efficacy and safety on TNBC [13], and the articles of Hagasewa et al [15] and Ishikawa et al [16] analysed the same cohort of patients). Clinical evidence on twelve licensed drugs was found, and of these drugs, eleven out of 268 (4.1%) were included in ReDO_DB. Eleven studies out of 18 were retrospective studies [10–13, 17, 19, 20, 22, 25, 26], six were phase II and [14–16, 18, 21, 23] one was a phase I clinical trial [24] (see Figure 1 for more details). Retrospective studies ranged from 1995 to 2016, and six out of eleven studies analysed a USA cohort of patients [10, 12, 19, 20, 25, 26]. Eight studies were performed using medical records [10, 12, 17, 19, 20, 22, 25, 26], one was based on disease registries [11] and two reported the results of previous clinical trials [13]. Of the 18 clinical studies collected, four analysed the efficacy of beta blockers (BB) [11–13], five of non-steroidal anti-inflammatory drugs (NSAIDs) [17–21], two of zoledronic acid [15, 16], one of metformin [10], one of tetramolybdate [14], one of itraconazole [22], one of esomeprazole [23], one of mifepristone [24] and two of statins [25, 26]. Outcomes retrieved from clinical studies were grouped, whenever possible, in pharmacological categories and summarised in Table 2.
Table 1. Characteristics of clinical studies about repurposing of old drugs for TNBC treatment.

| Reference                  | Study type                  | Database used (if observational) and data source type | Country       | Study period | Population                                                                 | Main exclusion criteria                                                                 | Drugs of interest |
|----------------------------|-----------------------------|-------------------------------------------------------|---------------|--------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------|
| Bayraktar et al 2012 [10]  | Retrospective study         | Breast Cancer Management System (Medical records and pharmacy data) | USA           | 1995–2007    | Women with TNBC who received adjuvant chemotherapy                          | - Metastatic or bilateral disease - Prior history of cancer - Resolved gestational diabetes - Diabetes diagnosed after adjuvant chemotherapy | Metformin         |
| Botteri et al 2013 [11]    | Retrospective cohort study  | Breast Cancer and Cardiology Division Databases of the European Institute of Oncology of Milan (Disease registries) | Italy         | 1997–2008    | Postmenopausal women operated for early primary TNBC                         | History of invasive cancer or metastatic disease                                      | Beta blockers     |
| Melhem-Bertrand et al 2011 [12] | Retrospective cohort study | Breast Cancer Management System Database (Medical chart and pharmacy data) | USA           | 1995–2007    | Women with invasive TNBC treated with neoadjuvant anthracyclines and taxane | - BB after neoadjuvant chemotherapy - Unknown receptors expression status - Incomplete records longer than 9 months between neoadjuvant chemotherapy initiation and surgery - Bilateral BC | Beta blockers     |
| Spera et al 2017 (1) [13]  | Retrospective cohort study  | Data from a randomised, double blind clinical trial (ROSE/TRIO-012) | Multicentric  | -            | Women with advanced TNBC                                                    | -                                                                                       | Beta blockers     |
| Spera et al 2017 (2) [13]  | Retrospective cohort study  | Data from a randomised, double blind clinical trial (BCIRG-005) | Multicentric  | -            | Women with node positive TNBC                                                | -                                                                                       | Beta blockers     |
| Chan et al 2017 [14]       | Phase II, open label, single arm study |                       | -            | -            | Women with stage II/III TNBC                                                 | - Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering the study - Pregnant women | Tetrathiomolybdate |
| Hasegawa et al 2015 [15]   | Phase II, open label, randomised study |                       | Multicentric (Japan) | 2010–2012    | Women with stage IIA/IIB TNBC                                                 | - Bilateral breast cancer or inflammatory breast cancer - Distant metastasis - History of chemotherapy, endocrine therapy, or radiotherapy | Zoledronic acid   |
| Ishikawa et al 2017 [16]   | Phase II, open label, randomised study |                       | Multicentric (Japan) | 2010–2012    | Women with stage IIA/IIB TNBC                                                 | - Bilateral breast cancer or inflammatory breast cancer - Distant metastasis - History of chemotherapy, endocrine therapy, or radiotherapy | Zoledronic acid   |
| Retsky et al 2012 [17]     | Retrospective study         | Data from medical records                                    | Belgium       | 2003–2008    | Women who underwent mastectomy with axillary dissection                      | - Previous ipsilateral surgery for breast cancer were excluded                           | Ketorolac         |
| Study Authors (Year) | Study Design | Location | Period | Study Population | Outcomes | Repurposed Drug |
|----------------------|--------------|----------|--------|------------------|----------|-----------------|
| Chow et al. (2013)   | Phase II, multicentre, single-arm study | -       | 2006-2010 | Women with primary breast cancer | - Distant metastasis - Multiple, bilateral breast cancer - Postmenopausal patients with both positive estrogen and progesterone receptor status and negative lymph node involvement - Pregnant women or women with suspected pregnancy - Prior history of invasive breast cancer | Celecoxib |
| Shiao et al. (2017)  | Retrospective study | Data from University of Texas Southwestern (UTSW) TNBC registry (Medical records) | USA 1998-2016 | Women with stage II/III TNBC | - Stage I patients | Aspirin/Clopidogrel |
| Williams (2018)      | Retrospective study | Electronical medical records | USA 2005-2013 | Women with primary operable stages I-III breast cancer | - Not clear use of aspirin - Not surgery - Not primary - Lack of follow up | Aspirin |
| Pierga et al. (2010) | Phase II, randomised study (Remagus 02) | -       | 2004-2000 | Women with stage II/III breast cancer | - | Celecoxib |
| Tsubamoto et al. (2014) | Retrospective study | Kohnan hospitals (Medical records) | Japan 2008-2012 | Women with TNBC | - Visceral (lungs, brain, and liver) metastasis | Itraconazole |
| Wang et al. (2015)   | Phase II, open label, randomised study | -       | - | Women with metastatic or recurrent breast cancer | - Brain metastases - Prior chemotherapy in the metastatic setting | Esomeprazol |
| Nanda et al. (2016)  | Phase I, randomised | -       | USA | Metastatic or locally advanced breast cancer | - Allergy or hypersensitivity to mifepristone, paclitaxel - Received more than 4 prior cytotoxic therapies for metastatic disease or prior nab-paclitaxel or mifepristone. - Pregnant or breast feeding | Mifepristone |
| Lacerda et al. (2014) | Retrospective study | IBC database - Breast Cancer Management System at MD Anderson Cancer Center (Medical records) | USA 1995-2011 | Patients with inflammatory breast cancer | - Stage IV patients - Patients who did not receive adjuvant postmastectomy radiation therapy - Patients with locoregional recurrence prior to radiation | Statins |
| Shaitelman et al. (2017) | Retrospective study | Data from MD Anderson Cancer Center (Medical records) | USA 1997-2012 | Women with invasive, non-metastatic TNBC | - | Statins |
Figure 1. Type of studies per drug. This shows the number of clinical trials (only phase 1 and 2 studies were found) and observational studies conducted per drug/pharmacological classes.

**Beta blockers (BBs)**

BBs were evaluated on postmenopausal women with operated early primary TNBC, on women with invasive TNBC (receiving neoadjuvant chemotherapy), and on women with advanced or nodal positive TNBC. Study populations ranged from 35 patients to 1,417 patients. In the study of Melhem-Bertrandt et al [12], using medical chart and pharmacy data from the Breast Cancer Management System Database in the USA, women with invasive TNBC receiving neoadjuvant chemotherapy plus BBs were compared to patients receiving only neoadjuvant chemotherapy between 1995 and 2007. Hazard ratio of recurrence free survival for women administered with chemotherapy plus BBs was 0.30 (95% CI, 0.10–0.87; \( p = 0.027 \)) and hazard ratio of overall survival was 0.35 (95% CI, 0.12–1.00; \( p = 0.05 \)) [12]. Also, in the retrospective study of Botteri et al [11] using Breast Cancer and Cardiology Division Databases in Italy and analysing 800 postmenopausal women diagnosed and operated for early primary TNBC between 1997 and 2008, BB users showed significant benefit when compared to not BB users. Breast cancer related events where lower in BB users (13.6% versus 27.9%; \( p = 0.02 \)) and hazard ratio of metastasis and BC death were significant (0.32: 95% CI 0.12–0.90; \( p = 0.031 \); 0.42: 95% CI 0.18–0.97; \( p = 0.042 \), respectively). The study of Spera et al [13], using data of a randomised, double blind clinical trial (ROSE/TRIO-012), showed significant benefit in women with advanced TNBC using BBs when compared to not users about progression free survival (Hazard ratio = 0.52; 95% CI, 0.34–0.80; \( p = 0.002 \)) but not in overall survival (Hazard ratio = 0.87; 95% CI 0.58–1.31; \( p = 0.504 \)). The second study presented by Spera et al [13] using also data from another randomised, double blind clinical trial (BCIRG-005) about women with node positive TNBC did not show any significant benefit of relapse free survival and overall survival (Hazard ratio = 0.69; 95% CI, 0.35–1.34; \( p = 0.269 \); 0.73; 95% CI, 0.35–1.48; \( p = 0.38 \), respectively).
Table 2. Outcomes for each clinical study.

| Reference | ARM1 | ARM2 | ARM3 | Population size (TNBC) | Average age (years) of TNBC patients | Follow up | Outcome | Outcome size | Effect size measures |
|-----------|------|------|------|-------------------------|--------------------------------------|-----------|---------|--------------|---------------------|
| Bayraktar et al 2012 [10] | Diabetic patients Metformin + Adj chemo + Adjuvant treatment | Diabetic patients Adj chemo alone | Not diabetic patients | 1,448 patients | ARM1: Median 53 ARM2: Median 51 ARM3: Median 58 | 62 months | 1) Distant metastasis free survival 2) Overall survival 3) Recurrence free survival | 1) ARM1, ARM2, ARM3 0.73 (0.58–0.83), 0.66 (0.52–0.77), 0.60 (0.57–0.62); p = 0.23 1) ARM2 versus ARM1: 1.63 (95% CI: 0.87–3.06); p = 0.13; ARM3 versus ARM1: 1.62 (95% CI: 0.97–2.71); p = 0.06 2) ARM1, ARM2, ARM3: 0.65 (0.51–0.76), 0.54 (0.51–0.56), p = 0.38 1) ARM2 versus ARM1: 1.37 (95% CI: 0.78–2.40); p = 0.27; ARM3 versus ARM1: 1.16 (95% CI: 0.87–1.57); p = 0.17 2) ARM1, ARM2, ARM3: 0.54 (0.51–0.56), 0.58 (0.55–0.59), p = 0.71 3) ARM2 versus ARM1: 1.28 (95% CI: 0.79–2.08); p = 0.31 |
| Botti et al 2013 [11] | Beta blockers users | Beta blockers non users | - | 800 patients | ARM1: Mean 62 ARM2: Mean 59 | ARM1: Median 72 months ARM2: median 68 months | 1) Breast Cancer-related events 2) Distant metastasis 3) Breast Cancer death | 1) 13.6% versus 27.9%; p = 0.015 2) 0.32 (95% CI: 0.12–0.90; p = 0.031) 3) 0.42 (95% CI: 0.18–0.97; p = 0.042) |
| Melhem-Bertrand et al 2011 [12] | Beta blockers + neoadjuvant therapy | Beta blockers non users | - | 1,417 patients | ARM1: Mean 47.5 ARM2: Mean 55 | ARM1: Median 55 months ARM2: Median 63 months | 1) Recurrence free survival 2) Overall survival | 1) 0.30; 95% CI: 0.10–0.87; p = 0.027 2) 0.35; 95% CI: 0.12–1.00; p = 0.05 |
| Spera et al 2017 [13] | Beta blockers users | Beta blockers non users | - | 1,144 patients | ARM1: Median 60 ARM2: Median 53 | Median: 25.1 months | 1) Progression free survival 2) Overall survival | 1) 0.52; 95% CI: 0.34–0.80; p = 0.002 2) 0.87; 95% CI: 0.58–1.31; p = 0.504 |
| Spera et al 2017 - 2 [13] | Beta blockers users | Beta blockers non users | - | 35 patients | - | - | 1) Relapse free survival 2) Overall survival | 1) 0.69; 95% CI: 0.35–1.34; p = 0.269 2) 0.73; 95% CI: 0.35–1.48; p = 0.384 |
| Study                        | Treatment                                                                 | Patients | Event free survival | Pathological complete response rates | Two-year event free rate |
|-----------------------------|---------------------------------------------------------------------------|----------|---------------------|--------------------------------------|-------------------------|
| Chan et al 2017 [14]        | Tetramylibdate                                                            | 36       | Med. 6.3 years      | -                                    | -                       |
| Hasegawa et al 2015 [15]    | Zoledronic acid + Neo-adj chemotherapy                                    | 34       | -                   | Pathological complete response rates  | -                       |
| Ishikawa et al 2017 [16]    | Zoledronic acid + Neo-adj chemotherapy                                    | 34       | -                   | Three years disease free survival    | -                       |
| Retsky et al 2012 [17]      | Ketorolac + Chemotherapy                                                  | Not spec. | 27.3 months        | Disease free survival                | Far superior disease-free survival in the first few years after surgery (no data shown) |
| Chow et al 2013 [18]        | Celecoxib (200mg) + Neo-adj chemo:                                        | 2        | -                   | 1) Pathological complete response 2) Near Pathological complete response | -                       |
Table 2. Outcomes for each clinical study. (continued)

| Study                          | Treatment Details                                                                 | Patients | Outcome Measures                                                                 | Results                                                                                                       |
|-------------------------------|-----------------------------------------------------------------------------------|----------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Shiao et al 2017 [19]         | Antiplatelet users + Possible chemotherapy                                      | 222      | ARM1: Median 55; ARM2: Median 50; 1) Five years Disease free survival, 2) Five years Overall survival, 3) Five years Distant metastasis rate | 1) ARM1: 80.4% (ARM2: 62.3%; 0.503 (0.261–0.970) p = 0.04; 2) ARM1: 77.2% (ARM2: 69% (0.343–1.239) p = 0.192; 3) ARM1: 8.8% (ARM2: 31.9%; 0.310 (0.132–0.729) p = 0.007 |
| Williams et al 2018 [20]      | Aspirin users + Possible chemotherapy                                           | 147      | 1) Overall survival, 2) Disease free survival                                    | No specific outcome for TNBC comparing ARM1 versus ARM2                                                   |
| Pierga et al 2010 [21]        | Celecoxib + Chemotherapy, Chemotherapy: Eight cycles of EC-D                   | 78       | Pathological complete response                                                   | 29.5% (95% CI: 19.7%–40.9%) Pathological complete response rates |
| Tsubamoto et al 2014 [22]     | Itraconazole + Chemotherapy, Chemotherapy: docetaxel, carboplatin, and gemicitabine, vinorelbine, bevacizumab | 13       | 1) Response rates, 2) Progession free survival, 3) Overall survival              | 1) 62% (95% CI: 35%–88%); 2) 10.8 months (95% CI: 7.6–15.3 months); 3) 20.4 months (95% CI: 13.1–41.4 months) |
| Wang et al 2015 [23]          | Esomeprazole low dose (80mg) + chemotherapy                                      | 15       | Time to progression                                                              | 1) 10.7 (ARM1+ARM2) and 5.8 months (ARM3); p = 0.011 Median time |
Table 2. Outcomes for each clinical study.

| Study | Treatment | Placebo | Mifepristone (300mg) | Paclitaxel | Placebo | Mifepristone (300mg) | Paclitaxel |
|-------|-----------|---------|-----------------------|------------|---------|-----------------------|------------|
| Nanda et al 2016 [24] | Mifepristone (300mg) + Paclitaxel | Placebo | 4 patients - No specific outcome for TNBC | Response rates | 3 years Risk of locoregional recurrence | Median 7.5 years | ARM1: 16 | ARM2: 86 |
| Lacerda et al 2014 [25] | statue + Postmastectomy radiation | Placebo | 4 patients - No information on treatments | | | | ARM1: 39% | ARM2: 54% |
| Shaitelman et al 2017 | Statin users - Patients with lipid/cholesterol levels | Placebo | 4 patients - No specific outcome for TNBC | | | | ARM1: 58% | ARM2: 70% |
| Metformin | Metformin The retrospective study of Bayraktar et al [10] using medical chart and pharmacy data from the Breast Cancer Management System Database compared women who received adjuvant chemotherapy with or without metformin in the USA between 1995 and 2007. In total, 1,448 patients (63 diabetic patients receiving metformin, 67 diabetic patients not receiving metformin and 1318 not diabetic patients). The 5 years survival estimates for distant metastasis free survival were 73% in the metformin group, 66% in the non-metformin group and 60% in the non-diabetic group (p = 0.23). Overall survival was 67% in the metformin group, 69% in the non-metformin group and 66% in the non-diabetic group (p = 0.58). Recurrence free survival was 65% in the metformin group, 64% in the non-metformin group and 54% in the non-diabetic group (0.38). Also, after adjustments, no significant survival outcomes were obtained.
| Tetramolybdate | Tetramolybdate The primary endpoint of phase II open label single arm study of Chan et al [14] was to assess the change in VEGFR2+ endothelial progenitor cells in women treated with tetramolybdate. The study, performed on 36 women with stage II/III TNBC during adjuvant setting, showed that two year event free survival was 90%.
| Zoledronic acid | Zoledronic acid The articles of Hasegawa et al [15] and Ishikawa [16] referred to the same phase II, open label, randomised study but analysed different outcomes in the same cohort of patients (34 women with stage IIA/IIIB TNBC) treated with zoledronic acid plus chemotherapy versus chemotherapy in neoadjuvant setting. Pathological complete response was not significant (p = 0.112) when comparing neoadjuvant chemotherapy plus zoledronic acid (6/17 (35.3%) CI: 12.6–58.0) with chemotherapy alone (2/17 (11.8%) CI: 0.0–27.1). Also for the 3 years disease free survival, neoadjuvant chemotherapy plus zoledronic acid showed no significant benefit compared to the neoadjuvant treatment alone (p = 0.077) despite the fact that the percentage of patients in treatment with zoledronic acid was higher compared to the other arm (94.1% versus 70.6%).
| NSAIDs | NSAIDs Celecoxib was analysed in two studies: the first, a phase II randomised study of Pierga et al [21] performed between 2004 and 2007, analysed 23 women with stage II/III TNBC comparing chemotherapy alone with chemotherapy plus celecoxib. The authors stated that celecoxib did not improve pathological complete response rates, but no specific comparison on this outcome were shown in the article for TNBC patients. The second study, a phase II multicentre open-label single arm study of Chow et al [18], analysed women...
with primary breast cancer. Unfortunately, only two patients with primary TNBC were included and authors could not show any result about this cohort.

Aspirin was analysed in two retrospective studies. The first retrospective study of Shiao et al [19] that collected medical records from University of Texas Southwestern TNBC registry, analysed a cohort of 222 women with stage II/III TNBC in the USA between 2005 and 2013. Sixty-five women were treated with anti-platelet therapy (as aspirin or clopidogrel) and 157 with no anti-platelet therapy. A percentage of patients in both arms (6.3% and 7.1%, respectively) did not receive chemotherapy. Five years disease free survival and 5 years distant metastasis hazard ratios was significantly improved in favour of the first arm (anti-platelet 80.4%, no anti-platelet 62.3%, HR: 0.503 (0.261–0.970); \( p = 0.04 \); anti-platelet 8.8%, no anti-platelet 31.9%, HR: 0.310 (0.132–0.729); \( p = 0.007 \), respectively). Five years overall survival hazard ratio was not significant between the two arms (HR: 0.652 (0.343–1.239); \( p = 0.192 \)). The second retrospective study of Williams et al [20] performed in USA used electronic medical records of 147 women with primary operable stages I-III TNBC (114 never used aspirin, 19 before diagnosis, and 14 after diagnosis) to analyse overall survival and disease-free survival between 2005 and 2013. Results of this study indicated that aspirin may have an impact on the pathogenesis of TNBC but do not seem to affect breast cancer survival when used after cancer diagnosis (results were presented only for the total cohort of breast cancer patients and not for TNBC subtype).

Finally, Retsky et al [17] showed the updated results of a retrospective study performed in Belgium using medical records between 2003 and 2008 [27], in which ketorolac plus chemotherapy was compared to chemotherapy alone in women who underwent mastectomy with axillary dissection. No information about the cohort (as for the number of patients with TNBC, age, etc...) was reported. Also, for the results the authors said that the group receiving chemotherapy plus ketorolac showed a ‘far superior disease free survival in the first few years after surgery’ but no data were shown in particular about TNBC.

**Itraconazole**

The article of Tsubamoto et al [22] reported the results of a retrospective study that used medical records of the Kohan hospital in Japan between 2008 and 2012 to analyse response rate, median progression-free survival and median overall survival of thirteen patients. TNBC patients who progressed after prior chemotherapy were treated with chemotherapy in combination with itraconazole. No comparison was made. The authors showed that response rate was 62\% ([CI], 35\%–88\%), progression free survival was 10.8 months (95\%CI, 7.6–15.3) and overall survival was 20.4 months (95\%CI: 13.1–41.4 months).

**Esomeprazole**

The phase II, open label, randomised study of Wang et al [23] analysed a cohort of 15 women with metastatic or recurrent TNBC (seven receiving only chemotherapy, two esomeprazole low dose and six esomeprazole high dose). The authors showed that the time to progression of patients receiving esomeprazole when compared to chemotherapy was significantly higher (10.7 versus 5.8 months; \( p = 0.011 \)).

**Mifepristone**

In the Phase I, randomised study of Nanda and colleagues performed in USA, four women with metastatic or locally advanced TNBC were analysed (those patients were allocated to mifepristone plus paclitaxel or placebo). Unfortunately, no information about patients allocation, nor any outcome information could be retrieved from this article [24].

**Statins**

The retrospective study of Shaitelman et al [26] used medical records from the MD Anderson Cancer Centre to investigate if women with stage I–III TNBC receiving statins at any time from diagnosis. The authors showed that patients receiving statins did not get any advantage compared to the non-statin users group (0.82 (0.57–1.16); 0.70 (0.47–1.03) relative risk of recurrence and breast cancer death, respectively); when a multivariate analysis was performed (taking in consideration cholesterol and triglyceride values, stage and chemotherapy, the authors showed that statin use was predictive for OS (HR: 0.10, \( p = 0.026 \), 95\% CI: 0.01–0.76)).
The retrospective study of Lacerda et al [25] using Breast Cancer Management database at MD Anderson Cancer Centre in USA between 1995 and 2011, analysed the risk of loco-regional recurrence at 3 years associated to the use of statins, in patients with inflammatory breast cancer who received adjuvant post-mastectomy radiotherapy. 102 patients underwent post-mastectomy radiation (86 patients) or post-mastectomy radiation plus statins (16 patients). Unfortunately no information about the outcome in TNBC patients was shown.

Clinicaltrials.gov

Searching the web site of clinicaltrials.gov (clinicaltrials.gov), we found only 17 drugs out of 286 presented in the ReDo_DB with ongoing or completed clinical trials for TNBC. Table 3 shows the list of trials and the recruitment status for each drug. As shown in Table 3, most part of the drugs present only one or few studies published on this website. In total, three studies are recruiting for the assessment of atorvastatin, two for metformin, two for mifepristone, and three for zoledronic acid.

Future directions

This review presents an overview of all the evidences about the repurposing of old, licensed, non-cancer-drugs in the treatment of TNBC, starting from preclinical evidence and going through current clinical trials. ReDO is an ambitious project aiming to investigate the repurposing of non-cancer-drugs in oncology, and ReDO_DB is a powerful tool that need to be dynamically implemented with recent findings, by adding to the database new drugs for which there are preclinical evidence, and by giving visitors a specific PubMed search string for each tumour and tumour subtypes. The ReDO approach is based on published literature and does not aim to identify new active compounds against cancer. Thus, the database does not include potential repurposing candidates identified through in silico modelling or other computational pharmacological approaches that, despite the interest for the research [28–31], unless validated by preclinical studies, represent only future hypothetical repurposed drugs and far from the aim of the ReDO project. The project, in particular, aims to drive scientist attention to investigate already approved non cancer-drugs in the oncology setting. Using this ReDO_DB, we found out that despite a lot of preclinical evidence was produced for drugs included in the database for the treatment of TNBC, only few of them were tested in clinical trials. Moreover, in clinical trials only few of the studies used a large sample of cases and gave explicit results on the repurposing of old drugs for TNBC. Some of the studies did not report any result for TNBC cohort when this is a part of a bigger BC cohort.

Beta Blockers (BBS) seem to be the more promising drugs in the repurposing for the treatment of TNBC. Three articles showed significant benefits of these drugs in women with advanced TNBC and in early primary TNBC patients treated with the combination of chemotherapy plus BBS [11–13]. Unfortunately, in clinicaltrials.gov we found no studies that specifically attempt to evaluate BBS within clinical trials for TNBC patients. One triple blinded phase II randomised trial evaluated the use of pre-operative propranolol (seven days before surgery) compared to placebo in 60 women with early stage surgically-resectable breast cancer. [32]. The authors showed that the treatment with propranolol reduced intra-tumoral mesenchymal transition and promoted immune cell infiltration reducing biomarkers associated with metastatic potential. Unfortunately, authors did not present results stratified for breast cancer sub-type.

While BBS demonstrated to be beneficial in the treatment of TNBC, metformin, a promising molecule in preclinical studies, did not show any efficacy in the treatment of women with TNBC. Bayraktar et al [10] showed that metformin does not improve survival outcomes in a population of TNBC women when compared to not users. Of note, two studies on the use of metformin in clinicaltrials.gov on TNBC patients are ongoing.

The articles of Shiao et al [19] and Williams et al [20] showed conflicting results on aspirin. While the first study showed a significant survival benefit in women with stage II/III by the use of aspirin, Williams et al [20] did not show this benefit in the breast cancer population examined (women with operable stage I-III TNBC).

Despite many studies trying to evaluate the use of statins in breast cancer treatment [33–36], in the literature search on PubMed, we retrieved only two retrospective studies on their use in the TNBC cohort. The article of Shaitelman et al [26] reported a non-significant improvement of OS for patients in the statin group (with the exception of the multivariate analysis), while the second study of Lacerda et al [25] did not show any results for TNBC patients.
| Drugs (REDO_DB) | Main indication | Mechanism of action | Clinical trial.gov |
|-----------------|-----------------|---------------------|-------------------|
| Acetylsalicylic acid | Analgesia, swelling, prophylaxis of venous embolism and further heart attacks or strokes | Cyclooxygenase inhibitor | (3) |
| Atorvastatin | Coronary heart disease, acute coronary syndrome | HMGCR inhibitor | NCT03358017 (Recruitment Status: Recruiting); NCT03872388 (Recruitment Status: Recruiting); NCT02021381 (Recruitment Status: Recruiting) |
| Celecoxib | OA, RA, JRA, AS, acute pain, primary dysmenorrhea | Cyclooxygenase inhibitor | NCT03599453 (Recruitment Status: Recruiting) |
| Doxycycline | Respiratory/urinary tract/ophthalmic infection | Metalloproteinase inhibitor | NCT02201381 (Recruitment Status: Recruiting) |
| Epalrestat | Diabetes | Aldose reductase inhibitor | NCT0244358 (Recruitment Status: Recruiting) |
| Flucytosine | Candida and/or Cryptococcus | Other antifungal | NCT02576665 (Recruitment Status: Active) |
| Imipramine | Depression | Norepinephrine reuptake inhibitor|serotonin reuptake inhibitor | NCT03122444 (Recruitment Status: Not yet recruiting) |
| Indomethacin | Analgesia | Cyclooxygenase inhibitor | NCT02950259 (Recruitment Status: Active) |
| Lansoprazole | Antacid | ATPase inhibitor | NCT03794596 (Recruitment Status: Not yet recruiting) |
| Leflunomide | Arthritis | Dihydropyrimidinase dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor | NCT03794446 (Recruitment Status: Recruiting) |
| Mebendazole | Parasitic infection | Tubulin polymerisation inhibitor | NCT02201381 (Recruitment Status: Recruiting) |
| Metformin | Diabetes | Insulin sensitizer | NCT01650506 (Recruitment Status: Completed); NCT02201381 (Recruitment Status: Recruiting) |
| Mifepristone | Abortifacient | Glucocorticoid receptor antagonist|progesterone receptor antagonist | NCT02788981 (Recruitment Status: Recruiting); NCT02014337 (Recruitment Status: Completed) |
| Omeprazole | Antacid | ATPase inhibitor | NCT02950259 (Recruitment Status: Active) |
| Ritonavir | Anti-retroviral | HIV protease inhibitor | NCT01099437 (Recruitment Status: Completed) |
| Zoledronic acid | Osteoporosis, prophylaxis of skeletal fractures and treat hypercalcemia of malignancy, treat pain from bone metastases | Bone resorption inhibitor | NCT03358017 (Recruitment Status: Recruiting); NCT02595138 (Recruitment Status: Active); NCT02347163 (Recruitment Status: Stopped due to the low accrual rate) |
Other authors showed significant results on the survival of TNBC patients treated with esomeprazole. Recently, one phase II study on activity of omeprazole on patients with operable TNBC independent of baseline Fatty acid synthase (FASN) expression was presented at the ASCO meeting. \cite{37} In vitro, proton pump inhibitors inhibit FASN activity and induce apoptosis in breast cancer cell lines. In this study, omeprazole in combination with anthracycline-taxane (AC-T) was administered to 42 patients until surgery, and pathologic complete response (pCR) was investigated. FASN positivity significantly decreased with omeprazole from 0.53 (SD = 0.25) at baseline to 0.38 (SD = 0.30; \( p = 0.02 \)), and the drug was well tolerated with no known grade 3 or 4 toxicities. Furthermore, the pCR rate was 71.4\% (95\% CI: 51.3–86.8) in FASN+ patients and 71.8 \% (95\% CI: 55.1–85.0) in all enrolled patients, demonstrating that the omeprazole in addition to neoadjuvant AC-T yields a promising pCR rate without adding toxicity.

For those drugs collected in ReDO_DB with favourable preclinical evidence or whose retrospective clinical trials were not so large to provide strong evidence, large retrospective cohort studies are needed to evaluate effectiveness. Further, as for BBs that have proven by retrospective studies to be effective in the treatment of TNBC patients, randomised clinical trials might be important to confirm the evidence of the repurposing.

**Final remarks**

Drug repurposing is a highly interesting novel strategy for the oncology community and ReDO_DB is a powerful tool that can give authors the opportunity to investigate weather non-anticancer drugs might be effective in cancer treatment. Some precision medicine studies, based on omics data, have included repurposed drugs and have reported interesting case reports of responses from patients \cite{38, 39}, however no one on TNBC. Due to the low number of therapeutic opportunities approved for TNBC, repurposing of old drugs seems a valuable approach for this particular type of cancer.

From the literature retrieved, BBs seemed to be the more promising drugs for the repurposing, while evidence about other drugs as NSAIDs still need to be assessed or proven for the treatment of TNBC.

**Conflicts of interest**

The authors declare that they have no conflict of interest

**Authors' contributions**

MZ and SC conceived the study. AS extracted the data. SD supervised the data extraction. MZ, SD, SC, AS, and PP contributed to the interpretation and discussion of study results. AS and SD drafted the manuscripts. All authors revised and approved the final version of the paper.

**Funding**

This study was supported by Fondazione Decima Regio ‘Olga e Raimondo Curri’, Via Cimarra 44-B, Roma.
References

1. Perou CM (2010) Molecular stratification of ripple-negative breast cancers Oncologist 15(5S) 39–48 https://doi.org/10.1634/theoncologist.2010-5S-39

2. Brouckaert O, Wildiers H, and Floris G, et al (2012) Update on triple-negative breast cancer: prognosis and management strategies Int J Women's Health 4 511–520. PMID: 23071421 PMCID: 3469230

3. Gucalp A and Traina TA (2011) Triple-negative breast cancer: adjuvant therapeutic options Chemother Res Pract 2011 696208

4. Dent R, Trudeau M, and Pritchard KI, et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13(15) 4429–4434 https://doi.org/10.1158/1078-0432.CCR-06-3045 PMID: 17671126

5. Spini A, Roberto G, and Gini R, et al (2019) Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: a systematic review Neoplasma 66(6) 963–970 https://doi.org/10.4149/neo_2019_190110N34 PMID: 31607128

6. Pushpakom S, Iorio F, and Eyers PA, et al. (2019) Drug repurposing: progress, challenges and recommendations Nat Rev Drug Discov 18(1) 41–58 https://doi.org/10.1038/nrd.2018.168

7. Goldstein DA, Stemmer SM, and Gordon N (2016) The cost and value of cancer drugs—are new innovations outpacing our ability to pay? Isr J Health Policy Res 5 40 https://doi.org/10.1186/s13584-016-0097-0

8. Pantziarka P, Verbaanderd C, and Sukhatme V, et al (2018) ReDO_DB: the repurposing drugs in oncology database Ecancermedicalscience 12 886 https://doi.org/10.3332/ecancer.2018.886

9. ClinicalTrials.gov [https://clinicaltrials.gov/] Date accessed: 31/03/19

10. Bayraktar S, Hernandez-Aya LF, and Lei X, et al. (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer Cancer 118(5) 1202–1211 https://doi.org/10.1002/cncr.26439

11. Botteri E, Munzione E, and Rotmensz N, et al (2013) Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast cancer research and treatment Breast Cancer Res Treat 140(3) 567–575 https://doi.org/10.1007/s10549-012-2654-3 PMID: 23912960

12. Melhem-Bertrandt A, Chavez-Macgregor M, and Lei X, et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 29(19) 2645–2652 https://doi.org/10.1200/JCO.2010.33.4441 PMID: 21632501 PMCID: 3139371

13. Spera G, Fresco R, and Fung H, et al (2017) Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study Ann Oncol 28(8) 1836–1841 https://doi.org/10.1093/annonc/mdx264 PMID: 28520849

14. Chan N, Willis A, and Kornhauser N, et al (2017) Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases Clin Cancer Res 23(3) 666–676 https://doi.org/10.1158/1078-0432.CCR-16-1326

15. Hasegawa Y, Tanino H, and Horiguchi J, et al (2015) Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study) PLoS One 10(12) e0143643 https://doi.org/10.1371/journal.pone.0143643 PMID: 26633806 PMCID: 4669153

16. Ishikawa T, Akazawa K, and Hasegawa Y, et al (2017) Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer J Surg Res 220 46–51 https://doi.org/10.1016/j.jss.2017.05.066 PMID: 29180210

17. Retisky M, Rogers R, and Demichelis R, et al (2012) NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup Breast Cancer Res Treat 134(2) 881–888 https://doi.org/10.1007/s10549-012-2094-5 PMID: 22622810
18. Chow LWC, Tung SY, and Ng T-Y, et al (2013) Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study Expert Opin Investig Drugs 22(3) 299–307 https://doi.org/10.1517/13543784.2013.766715 PMID: 23394482
19. Shiao J, Thomas KM, and Rahimi AS, et al (2017) Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients Breast Cancer Res Treat 161(3) 463–471 https://doi.org/10.1007/s10549-016-4081-8
20. Williams AD, Li YR, and So A, et al (2018) The impact of aspirin use on breast cancer subtype and clinical course J Surg Res 230 71–79 https://doi.org/10.1016/j.jss.2018.04.040 PMID: 30100043
21. Pierga J-Y, Delaloge S, and Espié M, et al (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients Breast Cancer Res Treat 122(2) 429–437 https://doi.org/10.1007/s10549-010-0939-3 PMID: 20480225
22. Tsubamoto H, Sonoda T, and Inoue K. (2014) Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer Anticancer Res 34(7) 3839–3844 PMID: 24928411
23. Wang B-Y, Zhang J, and Wang J-L, et al (2015) Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer J Exp Clin Cancer Res 34 85 https://doi.org/10.1186/s13046-015-0194-x PMID: 27386391 PMCID: 4929099
24. Nanda R, Stringer-Reasor EM, and Saha P, et al (2016) A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer Springerplus 5(1) 947 https://doi.org/10.1186/s40064-016-2457-1 PMID: 27632168 PMCID: 4929099
25. Lacerda L, Reddy JP, and Liu D, et al (2014) Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation Stem Cells Transl Med 3(7) 849–856 https://doi.org/10.5966/sctm.2013-0204 PMID: 24833589 PMCID: 4073823
26. Shaitelman SF, Stauder MC, and Allen P, et al (2017) Impact of statin use on outcomes in triple negative breast cancer J Cancer 8(11) 2026–2032 https://doi.org/10.7150/jca.18743 PMID: 28819403 PMCID: 5559964
27. Forget P, Berlière M, and van Maanen A, et al (2013) Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial Med Hypotheses 81(4) 707–712 https://doi.org/10.1016/j.mehy.2013.07.033 PMID: 23937996
28. Vitali F, Cohen LD, and Demartini A, et al (2016) A network-based data integration approach to support drug repurposing and multi-target therapies in triple negative breast cancer PLoS One 11(9) e0162407 https://doi.org/10.1371/journal.pone.0162407 PMID: 27632168 PMCID: 5025072
29. Turanli B, Karagoz K, and Gulfidan G, et al (2018) A network-based cancer drug discovery: from integrated multi-omics approaches to precision medicine Curr Pharm Des 24(32) 3778–3790 https://doi.org/10.2174/1873858924666181106095959 PMID: 30398107
30. Ocana A and Pandiella A (2017) Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies Oncotarget 18(8):22218–34 https://doi.org/10.18632/oncotarget.14731
31. Bianchini G, Balko JM, and Mayer IA, et al (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat Rev Clin Oncol 13(11) 674–690 https://doi.org/10.1038/nrclinonc.2016.66 PMID: 27184417 PMCID: 5461122
32. Hiller JG, Cole SW, and Crone EM, et al (2020) Pre-operative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II randomized trial Clin Cancer Res 26(8) 1803–1811 https://doi.org/10.1158/1078-0432.CCR-19-2641
33. Ahern TP, Pedersen L, and Tarp M, et al (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study J Natl Cancer Inst 103(19) 1461–1468 https://doi.org/10.1093/jnci/djr291 PMID: 21813413 PMCID: 3186780
34. Boudreau DM, Yu O, and Chubak J, et al (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. *Breast Cancer Res Treat* **144**(2) 405–416. https://doi.org/10.1007/s10549-014-2870-5 PMID: 24557337 PMCID: 3988288

35. Kwan ML, Habel LA, and Flick ED, et al (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. *Breast Cancer Res Treat* **109**(3) 573–579. https://doi.org/10.1007/s10549-007-9683-8

36. Murtola TJ, Visvanathan K, and Artama M, et al Statin use and breast cancer survival: a nationwide cohort study from Finland. *PLoS One* **9**(10) e110231

37. Sardesai SD, Thomas A, and Gallagher C, et al (2020) Inhibiting fatty acid synthase in operable triple negative breast cancer. *J Clin Oncol* **38**(suppl; abstr 584) https://doi.org/10.1200/JCO.2020.38.15_suppl.584

38. Brown RE, Buryanek J, and McGuire MF (2017) Metformin and melatonin in adrenocortical carcinoma: morphoproteomics and biomedical analytics provide proof of concept in a case study. *Ann Clin Lab Sci* **47**(4) 457–465 PMID: 28801373

39. Jones MR, Schrader KA, and Shen Y, et al (2016) Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. *Ann Oncol* **27**(5) 801–806 https://doi.org/10.1093/annonc/mdw060 PMID: 27022066 PMCID: 4843189
Table S1. Search strings.

| PubMed String: 3 blocks combined with AND |
|------------------------------------------|
| Pathology block                           |
| “Triple negative breast cancer”[Title/Abstract] OR “TNBC”[Title/Abstract] OR “Triple negative breast neoplasms”[Mesh] |
| Intervention Block                        |
| “Repurposing”[All Fields] OR “Repurpose”[All Fields] OR “Repositioning”[All fields] OR “Reposition”[All Fields] |
| Type of study Block                       |
| “Clinical trial”[Publication type] OR “Clinical Study”[Publication Type] OR “Epidemiologic Studies”[Mesh] |

Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB.

| Drugs | Main indication            | Mechanism of action            | References                                                                 |
|-------|---------------------------|--------------------------------|-----------------------------------------------------------------------------|
| Acetaminophen | Analgesia | TRPA1 inhibitor | − Afshar E, Hashemi-Arabi M, Salami S, Peirouvi T, Pouriran R. Screening of acetaminophen-induced alterations in epithelial-to-mesenchymal transition-related expression of microRNAs in a model of stem-like triple-negative breast cancer cells: The possible functional impacts. Gene. 2019 Jun 20;702:46–55. |
| Acetazolamide | Glaucoma, diuretic, epilepsy | Carbonic anhydrase inhibitor | − Ivanova L, Zandberga E, Šiliņa K, Kalniņa Z, Ābols A, Endzelinš E, et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemother Pharmacol. 2015 Feb;75(2):235–46.  
− Tatiparti K, Sau S, Gawde KA, Iyer AK. Copper-Free "Click" Chemistry-Based Synthesis and Characterisation of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia. Int J Mol Sci. 2018 Mar 13;19(3). |
| Drug                       | Category                        | Mechanism                                      | Reference                                                                 |
|----------------------------|---------------------------------|------------------------------------------------|---------------------------------------------------------------------------|
| Acetylsalicylic acid       | Analgesia, swelling, prophylaxis of venous embolism and further heart attacks or strokes | Cyclooxygenase inhibitor | - Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 11:20(1):150.  
- Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. Preclinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs. 2018;36(5):782–96.  
- Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep. 2016 Jan 5;6:18673.  
- Maity G, Chakraborty J, Ghosh A, Haque I, Banerjee S, Banerjee SK. Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. J Cell Commun Signal. 2019 Jan 4  
- Hsieh C-C, Wang C-H. Aspirin Disrupts the Crosstalk of Angiogenic and Inflammatory Cytokines between 4T1 Breast Cancer Cells and Macrophages. Mediators Inflamm. 2018:2018:6380643  
- Basudhar D, Glynn SA, Greer M, Somasundaram V, No JH, Scheiblin DA, et al. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc Natl Acad Sci USA. 2017 05:114(49):13030–5  
- Lee YR, Kim KM, Jeon BH, Choi S. Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation. Oncotarget. 2015 Sep 15;6(27):23383–98  
- Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15;83(6):723–32 |
| Albendazole                | Parasitic infection             | Tubulin polymerisation inhibitor               | - Priotti J, Baglioni MV, García A, Rico MJ, Leonard D, Lamas MC, et al. Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer. AAPS PharmSciTech. 2018 Nov;19(8):3734–41. |
| Amiloride                  | In congestive heart failure or hypertension treated with thiazides, to conserve potassium | Sodium channel blocker | - Amith SR, Wilkinson JM, Baksh S, Fliegel L. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells. Oncotarget. 2015 Jan 20;6(2):1262-75. |
| Aprepitant                  | Nausea, vomiting                | Tachykinin antagonist                          | - Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols KT, Tweardy DJ. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. Biomed Res Int. 2016;2016:1959270 |
| Artesunate                 | Malaria                         | DNA synthesis inhibitor                        | - Greenshields AL, Fernando W, Hoskin DW. The anti-malarial drug artemesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp Mol Pathol. 2019;107:10-22. |
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Drug               | Condition                        | Mode of Action                        | Reference                                                                                     |
|--------------------|----------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------|
| Ascorbic acid      | Scurvy                           | Antioxidant                           | Wu C-W, Liu H-C, Yu Y-L, Hung Y-T, Wei C-W, Yiang G-T. Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways. Oncol Rep. 2017 Apr;37(4):2177–84. Isolated Ascorbic acid combined with methotrexate enhanced H2O2 accumulation and induced caspase-3 and p38 MAPK activation in MDA-MB 231 triple-negative breast cancer cells. J Cancer Res. 2017 Sep 1;8(9):4108–19. |
| Atenolol           | Hypertension, angina pectoris     | Adrenergic receptor antagonist        | Hatem E, Azzi S, El Banna N, He T, Heneman-Masurel A, Vernis L, et al. Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer. J Natl Cancer Inst. 2018 Nov 20. Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep. 2016 Jan 5;6:18673. |
| Atorvastatin       | Coronary heart disease, acute coronary syndrome | HMGCR inhibitor                      | Rachner TD, Göbel A, Thiele S, Rauner M, Benad-Meiner P, Hadji P, et al. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res. 2014 Feb 14;16(1):R20. Mafuvadze B, Liang Y, Hyder SM. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor. Oncol Rep. 2014 Oct;32(4):1727–33. Koohestanimobarhan S, Salami S, Imeni V, Mohammadi Z, Bayat O. Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway. J Cell Biochem. 2018 Sep 6. |
| Auranofin          | RA                               | NFkB pathway inhibitor                | Raninga PV, Lee AC, Sinha D, Shih Y-Y, Mittal D, Makhale A, et al. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. Int J Cancer. 2019 May 15. Hatem E, Azzi S, El Banna N, He T, Heneman-Masurel A, Vernis L, et al. Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer. J Natl Cancer Inst. 2018 Nov 20. |
| Azithromycin       | Bacterial infection, CAP, PID     | Bacterial 50S ribosomal subunit inhibitor | Fu S, Lin J. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells. Anticancer Res. 2018 Nov;38(11):6271–9. Fu S, Chen X, Lo H-W, Lin J. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Lett. 2019 Apr 28;448:11–9. Tian J, Chen X, Fu S, Zhang R, Pan L, Cao Y, et al. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun;175(3):553–66. |
| Bazedoxifene       | Osteoporosis                      | selective estrogen receptor modulator (SERM) | Fu S, Lin J. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells. Anticancer Res. 2018 Nov;38(11):6271–9. Fu S, Chen X, Lo H-W, Lin J. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Lett. 2019 Apr 28;448:11–9. Tian J, Chen X, Fu S, Zhang R, Pan L, Cao Y, et al. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun;175(3):553–66. |
| Bepridil           | Hypertension and chronic stable angina | Calcium channel blocker               | Park S-H, Chung YM, Ma J, Yang Q, Berek JS, Hu MC-T. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):42110–25. |
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Drug               | Deficiency/Disease                                                                 | Mechanism/Target                  | Reference                                                                 |
|--------------------|-----------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------|
| Calcitriol         | Vitamin D deficiency                                                              | Vitamin D receptor agonist         | - Martínez-Reza I, Díaz L, Barrera D, Segovia-Mendoza M, Pedraza-Sánchez S, Soca-Chafre G, et al. Calcitriol Inhibits the Proliferation of Triple-Negative Breast Cancer Cells through a Mechanism Involving the Proinflammatory Cytokines IL-1β and TNF-α. J Immunol Res. 2019;2019:6384278  
- Zheng W, Cao L, Ouyang L, Zhang Q, Duan B, Zhou W, et al. Anticancer activity of 1.25-(OH)2D3 against human breast cancer cell lines by targeting Ras/MEK/ERK pathway. Onco Targets Ther. 2019;12:721–32  
- Bijian K, Kaldre D, Wang T-T, Su J, Bouttier M, Boucher A, et al. Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. J Steroid Biochem Mol Biol. 2018;177:135–9  
- Bohl L, Guizzardi S, Rodríguez V, Hinrichsen L, Rozados V, Cremonezzi D, et al. Combined calcitriol and menadione reduces experimental murine triple negative breast tumor. Biomed Pharmacother. 2017 Oct;94:21–6  
- Shan NL, Wahler J, Lee HJ, Bak MJ, Gupta SD, Maehr H, et al. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. J Steroid Biochem Mol Biol. 2017;173:122–9  
- Thakkar A, Wang B, Picon-Ruiz M, Buchwald P, Ince TA. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Res Treat. 2016;157(1):77–90  
- Richards SE, Weierstahl KA, Kelts JL. Vitamin D effect on growth and vitamin D metabolizing enzymes in triple-negative breast cancer. Anticancer Res. 2015 Feb;35(2):805–10  
- Lopes N, Carvalho J, Durães C, Sousa B, Gomes M, Costa JL, et al. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res. 2012 Jan;32(1):249–57 |
| Carglumic acid     | Hyperammonemia in N-acetylglutamate synthase deficiency                             | Carbamoyl phosphate synthase activator | - Chen C-T, Chen Y-C, Yamaguchi H, Hung M-C. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. Am J Cancer Res. 2015;5(12):3560–9 |
| Celecoxib          | OA, RA, JRA, AS, acute pain, primary dysmenorrhea                                   | Cyclooxygenase inhibitor           | - Ma Q, Gao Y, Wei D-F, Jiang N-H, Ding L, He X, et al. The effects of celecoxib on the proliferation and ultrastructural changes of MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018 Jun;42(3):289–94  
- Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012 Dec 1;325(1):63–71 |
| Drug          | Condition                        | Antimarial agent                                                                 |
|--------------|----------------------------------|----------------------------------------------------------------------------------|
| Chloroquine  | Malaria, Extraintestinal Amebiasis | - Liang DH, Choi DS, Ensror JE, Kaiparettu BA, Bass BL, Chang JC. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett. 2016 01;376(2):249–58  
- Bouchard G, Therriault H, Geha S, Bérubé-Lauzière Y, Bujold R, Saucier C, et al. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model. BMC Cancer. 2016 10;16:361  
- Tuomela J, Sandholm J, Kauppila JH, Lehenkari P, Harris KW, Selander KS. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665–72  
- Chang C-T, Korivi M, Huang H-C, Thiyagarajan V, Lin K-Y, Huang P-J, et al. Inhibition of ROS production, autophagy or apoptosis signaling reversed the anticancer properties of Antrodia salmonea in triple-negative breast cancer (MDA-MB-231) cells. Food Chem Toxicol. 2017 May;103:1–17.  
- Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012 Apr;11(4):973–83.  
- Hu J, Zhang Y, Jiang X, Zhang H, Gao Z, Li Y, et al. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine. J Exp Clin Cancer Res. 2019 May 28;38(1):225.  
- Choi DS, Blanco E, Kim Y-S, Rodriguez AA, Zhao H, Huang TH-M, et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells. 2014 Sep;32(9):2309–23  
- Wang Z, Shi X, Li Y, Fan J, Zeng X, Xian Z, et al. Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis. 2014 Dec 11;5:e1563  
- Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Erahman GEFA-E, et al. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018 Nov 27;37(1):286  
- Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012 Dec 1;325(1):63–71  
- Lefort S, Joffre C, Kieffer Y, Givel A-M, Bourachot B, Zago G, et al. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy. 2014;10(12):2122–42  
- Chen M, He M, Song Y, Chen L, Xiao P, Wan X, et al. The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. Int J Mol Med. 2014 Jul;34(1):276–82  
- Abdel-Mohsen MA, Abdel Malak CA, El-Shafey ES. Influence of copper (I) nicotinate complex and autophagy modulation on doxorubicin-induced cytotoxicity in HCC1806 breast cancer cells. Adv Med Sci. 2019 Mar;64(1):202–9 |
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Drug               | Disease                                                                 | Effect                                                                 | Reference                                                                 |
|--------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Chlorpromazine     | Psychotic disorders, nausea and vomiting, anxiety, hiccups              | Dopamine receptor antagonist                                           | Zhao Y-Q, Yin Y-Q, Liu J, Wang G-H, Huang J, Zhu L-J, et al. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer. Acta Pharmacol Sin. 2016 Sep;37(9):1237–5 |
| Cholecalciferol    | Vitamin D deficiency                                                   |                                                                       | Kutlehria S, Behl G, Patel K, Dodapaneni R, Khora I, Chowdhury N, et al. Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer. AAPS PharmSciTech. 2018 Feb;19(2):792–802. |
| Ciprofloxacin      | Antibiotic                                                             | Bacterial DNA gyrase inhibitor                                         | Beberok A, Wrzéniok D, Rok J, Rzepka Z, Respondek M, Buszman E. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Int J Oncol. 2018 Mar 8 |
| Clotrimazole       | Fungal infections                                                      | Cytochrome P450 inhibitor|imidazoline receptor ligand | Zhang P, Yang X, Yin Q, Yi J, Shen W, Zhao L, et al. Inhibition of SK4 Potassium Channels Suppresses Cell Proliferation, Migration and the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells. PLoS ONE. 2016;11(4):e0154471. |
| Colchicine         | Gout                                                                   | Microtubule inhibitor                                                 | Lindamulage IK, Vu H-Y, Karthikeyan C, Knockleby J, Lee Y-F, Trivedi P, et al. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRPI function. Sci Rep. 2017;31(7):10298. |
| Danazol            | Endometriosis, fibrocystic breast disease, hereditary angioedema       | Estrogen receptor antagonist|progesterone receptor agonist | Deka SJ, Roy A, Ramakrishnan V, Manna D, Trivedi V. Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells. Chem Biol Drug Des. 2017;89(6):953–63 |
| Deferasirox       | Acute iron intoxication, chronic iron overload                        | Chelating agent                                                       | Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely J-L, Vacher S, et al. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers. J Pathol. 2018 Sep;246(1):103–14 |
| Deferiprone        | Iron overload in thalassemia major                                    | Chelating agent                                                       | Knickle A, Fernando W, Greenshields AL, Rupasinghe HPV, Hoskin DW. Myricetin-induced apoptosis of triple-negative breast cancer cells is mediated by the iron-dependent generation of reactive oxygen species from hydrogen peroxide. Food Chem Toxicol. 2018 Aug;118:154–67 |
| Digitoxin          | Congestive HF, atrial fibrillation, atrial flutter, PAT, cardiogenic shock | ATPase inhibitor                                                      | Kulkarni YM, Yakisich JS, Azad N, Venkatadri R, Kaushik V, O'Doherty G, et al. Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells. Tumour Biol. 2017 Jun;39(6):1010428317705331 |
| Digoxin            | Heart failure, atrial fibrillation                                    | ATPase inhibitor                                                      | Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA. 2014 Dec 16;111(50):E5429-5438 |
| Dipyridamole       | Thromboembolism Prophylaxis Post-Cardiac Valve Replacement            | Phosphodiesterase inhibitor                                           | Spano D, Marshall J-C, Marino N, De Martino D, Romano A, Scoppettuolo MN, et al. Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis. 2013 Jan;30(1):47–68 |
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Drug               | Condition                  | Function                        | References                                                                                                                                 |
|--------------------|----------------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Disulfiram         | Chronic alcoholism         | Aldehyde dehydrogenase inhibitor | - Kim JY, Lee N, Kim Y-J, Cho Y, An H, Oh E, et al. Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. Cancer Lett. 2017 01;386:151–60.  
- Kim Y-J, Kim JY, Lee N, Oh E, Sung D, Cho T-M, et al. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. Biochem Biophys Res Commun. 2017 May 13;486(4):1069–76.  
- Robinson TJW, Pai M, Liu JC, Vizeacoumar F, Sun T, Egan SE, et al. High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle. 2013 Sep 15;12(18):3013–24.  
- Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013 Oct 1;109(7):1876–85.  
- Wu L, Meng F, Dong L, Block CJ, Mitchell AV, Wu J, et al. Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC. Sci Rep. 2019 Jan 18;9(1):236. |
| Doxycycline        | Respiratory/urinary tract/ophthalmic infection | Metalloproteinase inhibitor | - Lin C-C, Lo M-C, Moody RR, Stevers NO, Tinsley SL, Sun D. Doxycycline targets aldehyde dehydrogenase-positive breast cancer stem cells. Oncol Rep. 2018 Jun;39(6):3041–7. |
| Dutasteride        | Benign prostatic hyperplasia | 5 alpha reductase inhibitor     | - von Wahlde M-K, Hülsewig C, Ruckert C, Götte M, Kiesel L, Bernemann C. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling. Gynecol Endocrinol. 2015 Feb;31(2):160–4. |
| Esomeprazole       | Antacid                     | ATPase inhibitor                | - Goh W, Sleptsova-Freidrich I, Petrovic N. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439–46 |
| Fasudil            | Vasodilator                 | Rho associated kinase inhibitor | - Guerra FS, Oliveira RG de, Fraga CAM, Mermelstein CDS, Fernandes PD. ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells. Sci Rep. 2017 20;7(1):13723. |
| Fenofibrate        | Hyperlipidemia              | PPAR receptor agonist           | - Li T, Zhang Q, Zhang J, Yang G, Shao Z, Luo J, et al. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway. BMC Cancer. 2014 Feb 16;14:96. |
| Fingolimod         | Multiple Sclerosis          | Immunosuppressant| sphingosine phosphate receptor agonist | - Martin JL, Julović SM, Lin MZ, de Silva HC, Boyle FM, Baxter RC. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Breast Cancer Res. 2017 Aug 4;19(1):90.  
- Alshaker H, Wang Q, Srivats S, Chao Y, Cooper C, Pchejetski D. New FTY720-doxetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. Breast Cancer Res Treat. 2017 Oct;165(3):531–43  
- Hait NC, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H, et al. The phosphonylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis. 2015 Jun 8;4:e156 |
| Drug            | Condition       | Mechanism/Target                     | Reference                                                                 |
|-----------------|-----------------|--------------------------------------|---------------------------------------------------------------------------|
| Flubendazole    | Parasitic infection | Tubulin polymerisation inhibitor     | - Oh E, Kim Y-J, An H, Sung D, Cho T-M, Farrand L, et al. Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int J Cancer. 2018 15;143(8):1978–93  
- Zhang L, Guo M, Li J, Zheng Y, Zhang S, Xie T, et al. Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer. Mol Biosyst. 2015 Nov;11(11):2860–6. |
| Fluoxetine      | Depression      | Selective serotonin reuptake inhibitor (SSRI) | - Sun D, Zhu L, Zhao Y, Jiang Y, Chen L, Yu Y, et al. Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. Cell Prolif. 2018 Apr;51(2):e12402.  
- Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desal S, et al. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol. 2015 Dec 10;6(6):299–311 |
| Fluvastatin     | Hyperlipidemia  | HMGCR inhibitor                       | - Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 11;20(1):150. |
| Ganciclovir     | Anti-viral      | DNA polymerase inhibitor              | - Castillo-Rodríguez RA, Arango-Rodríguez ML, Escobedo L, Hernandez-Baltazar D, Gompel A, Forgez P, et al. Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice. PLoS ONE. 2014;9(5):e97151  
- Devulapally R, Lee T, Barghava-Shah A, Sekar TV, Foygel K, Bachawal SV, et al. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy. Nanomedicine (Lond). 2018;13(9):1051–66 |
| Hydralazine     | Hypertension    | Vasodilator                           | - Jiang Y, Huang Y, Cheng C, Lu W, Zhang Y, Liu X, et al. Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells. Exp Mol Pathol. 2011 Dec;91(3):768–74 |
| Hydroxychloroquine | Malaria         |                                      | - Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeyesundara N, Leung A, et al. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res. 2014 Jun 15;20(12):3159–73 |
| Indomethacin    | Analgesia       | Cyclooxygenase inhibitor              | - Basudhar D, Glynn SA, Greer M, Somasundaram V, No JH, Scheiblin DA, et al. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc Natl Acad Sci USA. 2017 05;114(49):13030–5. |
| Ivermectin     | Parasitic infection | Benzodiazepine receptor agonist      | - Kwon Y-J, Petrie K, Leibovitch BA, Zeng L, Mezei M, Howell L, et al. Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 Aug;14(8):1824–36 |
| Leflunomide     | Arthritis       | Dihydroorotate dehydrogenase inhibitor| - Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2017;7(4):391–9.  
- Jin U-H, Lee S-O, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer. 2014 Jul 9;14:498. |
| Drug     | Disease               | Mechanism                               | Reference                                                                                                                                           |
|----------|-----------------------|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Losartan | Hypertension          | Angiotensin receptor antagonist         | - Hu C, Liu X, Ran W, Meng J, Zhai Y, Zhang P, et al. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials. 2017 Nov;144:60–72 |
|          |                       |                                         | - Song L, Tao X, Lin L, Chen C, Yao H, He G, et al. Cerosomal Lovastatin Nana-hybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy. ACS Appl Mater Interfaces. 2018 Feb 28;10(8):7022–30 |
|          |                       |                                         | - Zhang N, Liang X, Gao C, Chen M, Zhou Y, Krueger CJ, et al. Loading Lovastatin into Camptothecin-Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer. ACS Appl Mater Interfaces. 2018 Sep 5;10(35):29385–97. |
|          |                       |                                         | - Lin Z, Zhang Z, Jiang X, Kou X, Bao Y, Liu H, et al. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells. Oncotarget. 2017 Mar 14;8(11):17833–48 |
|          |                       |                                         | - Koohestanimobarhan S, Salami S, Imeni V, Mohammadi Z, Bayat O. Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway. J Cell Biochem. 2018 Sep 6 |
| Lovastatin | Hyperlipidemia       | HMGCR inhibitor                         | - Norton K-A, Wallace T, Pandey NB, Popel AS. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia. BMC Syst Biol. 2017 Jul 11;11(1):68 |
|          |                       |                                         | - in K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res. 2018 14;20(1):54. |
| Maraviroc | Anti-retroviral       | CC chemokine receptor antagonist        | - Kim T-H, Cho S-G. Melatonin-induced KISS1 expression inhibits triple-negative breast cancer cell invasiveness. Oncol Lett. 2017 Aug;14(2):2511–6 |
|          |                       |                                         | - Marques JHM, Mota AL, Oliveira JG, Lacerda JZ, Stefani JP, Ferreira LC, et al. Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies. Life Sci. 2018 Sep 1;208:131–8 |
|          |                       |                                         | - Lacerda JZ, Ferreira LC, Lopes BC, Aristizábal-Pachón AF, Bajgelman MC, Borin TF, et al. Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer. Microrna. 2019;8(3):237–47 |
|          |                       |                                         | - Jardim-Persassi BV, Arbab AS, Ferreira LC, Borin TF, Varma NRS, Iskander ASM, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PloS ONE. 2014;9(1):e85311 |
|          |                       |                                         | - Jardim-Persassi BV, Alexandre PA, Sonehara NM, de Paula-Junior R, Reis Júnior O, Fukumatsu H, et al. RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model. Sci Rep. 2019 Jan 30;9(1):966 |
| Mebendazole | Parasitic infection  | Tubulin polymerisation inhibitor        | - Zhang L, Bochkur Dratver M, Y zal T, Dong K, Nguyen A, Yu G, et al. Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):195–207 |
| Melatonin | Insomnia             | Melatonin receptor agonist/nitric oxide synthase inhibitor | - Valenciennes A, Plasse E, Naveau K, Montagno A, Zittoun R, et al. Melatonin improves the efficacy of the combination of paclitaxel/docetaxel/cisplatin in triple-negative breast cancer xenografts. Breast Cancer Res. Treat. 2019 Dec 12;181(3):639–50 |

Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)
| Metformin | Diabetes | Insulin sensitizer |
|-----------|----------|-------------------|
| Cheng G, Zielonka J, Hardy M, Ouari O, Chitambar CR, Dwinell MB, et al. | synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators. Oncotarget. 2019 May 28;10(37):3518–32 |  |
| Han Y, Li C-W, Hsu J-M, Hsu JL, Chan L-C, Tan X, et al. | Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. Am J Cancer Res. 2019;9(4):800–15 |  |
| Varghese S, Samuel SM, Varghese E, Kubatka P, Büsselberg D. | High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells. Biomolecules. 2019 08;9(1). |  |
| Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. | The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 11;20(1):150. |  |
| Wahdan-Alaswad RS, Edgerton SM, Salem HS, Thor AD. | Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res. 2018;4(1). |  |
| Amaral I, Silva C, Correia-Branco A, Martel F. | Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells. Biomed Pharmacother. 2018 Jun;102:94–101. |  |
| Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. | Preclinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs. 2018;36(5):782–96. |  |
| Shi P, Liu W, Tala null, Wang H, Li F, Zhang H, et al. | Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017;3:17010. |  |
| Wokoun U, Hellriegel M, Emons G, Gründker C. | Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors. Oncol Rep. 2017 Apr;37(4):2418–24. |  |
| Strekalova E, Malín D, Rajanala H, Cryns VL. | Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression. Breast Cancer Res Treat. 2017 Jun;163(3):435–47. |  |
| García-Castillo V, López-Urrutia E, Villanueva-Sánchez O, Ávila-Rodríguez MÁ, Zentella-Dehesa A, Cortés-González C, et al. | Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model. J Cancer. 2017;8(2):178–89. |  |
| Rico M, Baglioni M, Bondarenko M, Laluce NC, Rozados V, André N, et al. | Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874–89. |  |
| Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD. | Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. Cell Cycle. 2016;15(8):1046–59. |  |
| Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep. 2016 Jan 5;6:18673. |  |
| Marinello PC, da Silva TNX, Panis C, Neves AF, Machado KL, Borges FH, et al. | Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction. Tumour Biol. 2016 Apr;37(4):5337–46. |  |
| Drug          | Indication                     | Mechanism                                                                 | References                                                                                                                                                                                                 |
|--------------|--------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Methimazole  | Hyperthyroidism                | Antithyroid agent                                                         | Noori MS, O’Brien JD, Champa ZJ, Deosarkar SP, Lanier OL, Qi C, et al. Phenylethimazole and a thiazole derivative of phenylethimazole inhibit IL-6 expression by triple negative breast cancer cells. Eur J Pharmacol. 2017 May 15:803:130–7. |
| Mifepristone | Abortifacient                  | Glucocorticoid receptor antagonist|progesterone receptor antagonist | Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W, et al. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics. 2016;6(4):533–44.  
Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cal Y, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15;19(22):6163–72. |
| Minocycline  | Antibiotic                     | Bacterial 30S ribosomal subunit inhibitor                                  | Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen C-S, Kulp SK. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Exp Toxicol Pathol. 2016 Oct;68(9):505–15. |
| Montelukast  | Allergies                      | Leukotriene receptor antagonist                                           | Suknuntha K, Yubolphan R, Krueaprasertkul K, Srijirun S, Sibmooh N, Vivithanaporn P. Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells. Asian Pac J Cancer Prev. 2018 Mar 27;19(3):833–7. |
| Nelfinavir   | Anti-retroviral                 | HIV protease inhibitor                                                    | Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggregators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012 Dec 1;325(1):63–71. |
| Niclosamide  | Parasitic infection            | DNA replication inhibitor|STAT inhibitor                    | Yin L, Gao Y, Zhang X, Wang J, Ding D, Zhang Y, et al. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. Oncotarget. 2016 Jul 5;7(27):42126–38.  
Liu J, Chen X, Ward T, Pegram M, Shen K. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumour Biol. 2016 Jul;37(7):9825–35.  
Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, et al. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radiosensitivity in breast cancer and overcome of radiosensitivity with niclosamide. Oncogene. 2018;37(39):5292–304.  
Pindiprolu SKSS, Chintamaneni PK, Krishnamurthy PT, Ratna Sree Ganapathi K. Formulation-optimisation of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells. Drug Dev Ind Pharm. 2019 Feb;45(2):304–13. |
| Nicotinamide | Niacin Deficiency, Skin cancer chemotherapy | Protein synthesis stimulant                                                                 | Kim JY, Lee H, Woo J, Yue W, Kim K, Choi S, et al. Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer. Sci Rep. 2017 14;7(1):3466. |
| Nimodipine   | Hypertension                   | Calcium channel blocker                                                  | Jin U-H, Lee S-O, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer. 2014 Jul 9;14:498. |
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Drug        | Condition          | Reference                                                                 |
|-------------|--------------------|---------------------------------------------------------------------------|
| Noscapine   | Anti-tussive       | Doddapaneni R, Patel K, Chowdhury N, Singh M. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res. 2016 01;346(1):65–73. |
|             |                    | Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS ONE. 2011 Mar 15;6(3):e17733. |
|             |                    | Doddapaneni R, Patel K, Chowdhury N, Singh M. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 2017 Nov 20;7(1):15824. |
| Omega 3     | Hyperlipidemia     | Pizato N, Luzete BC, Kiffer LFMV, Corrêa LH, de Oliveira Santos I, Assumpção JAF, et al. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Sci Rep. 2018 31;8(1):1952. |
|             |                    | Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan Y-Y, et al. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019;38(12):2135–50. |
|             |                    | Pizato N, Kiffer LFMV, Luzete BC, Assumpção JAF, Correa LH, Melo HAB de, et al. Omega 3-DHA and Delta-Tocotrienol Modulate Lipid Droplet Biogenesis and Lipophagy in Breast Cancer Cells: the Impact in Cancer Aggressiveness. Nutrients. 2019 May 28;11(6). |
|             |                    | Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan Y-Y, et al. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019;38(12):2135–50. |
|             |                    | Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan Y-Y, et al. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019;38(12):2135–50. |
| Omeprazole  | Antacid            | Jin U-H, Lee S-O, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer. 2014 Jul 9;14:498. |
| Orlistat    | Obesity            | Paulmurugan R, Bhethanabotta R, Mishra K, Devulapally R, Foygel K, Sekar TV, et al. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer. Mol Cancer Ther. 2016 Feb 15;15(2):221–31 |
| Penfluridol | Psychotic disorders| Ranjan A, Gupta P, Srivastava SK, Penfluridol: An Antipsychotic Agent SuppressesMetastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis. Cancer Res. 2016 Feb 15;76(4):877–90. |
| Pentamidine | Parasitic infection| Her S, Cui L, Bristow RG, Allen C. Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. Radiat Res. 2016;185(5):549–62 |
| Drug                  | Disease       | Mechanism                             | Reference                                                                                                                                 |
|-----------------------|---------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Pentoxifylline        | Peripheral artery disease | Phosphodiesterase inhibitor | - Castellanos-Esparza YC, Wu S, Huang L, Buquet C, Shen R, Sanchez-Gonzalez B, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246–54 |
| Pirfenidone           | Anti-fibrotic  | TGF beta receptor inhibitor           | - Brooks D, Zimmer A, Wakefield L, Lyle LT, Difilippantonio S, Tucci FC, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9(34):23462–81. |
|                       |               |                                       | - Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016 Dec 13;7(50):82889–901 |
|                       |               |                                       | - Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, et al. p38y MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. Stem Cells. 2015 Sep;33(9):2738–47. |
| Propranolol           | Hypertension  | Adrenergic receptor antagonist        | - Rico M, Baglioni M, Bondarenko M, Laluce NC, Rozados V, André N, et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874–89. |
|                       |               |                                       | - Choy C, Raytis JL, Smith DD, Duenas M, Neman J, Jandial R, et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade. Oncol Rep. 2016 Jun;35(6):3135–42. |
|                       |               |                                       | - Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011 Oct;2(10):797–809. |
|                       |               |                                       | - Xie W-Y, He R-H, Zhang J, He Y-J, Wan Z, Zhou C-F, et al. β-blockers inhibit the viability of breast cancer cells by regulating the ERK/COX-2 signaling pathway and the drug response is affected by ADRB2 single-nucleotide polymorphisms. Oncol Rep. 2019 Jan;41(1):341–50. |
| Pyrimethamine         | Parasitic infection | Dihydrofolate reductase inhibitor   | - Egusquiaguirre SP, Yeh JE, Walker SR, Liu S, Frank DA. The STAT3 Target Gene TNFRSF1A Modulates the NF-κB Pathway in Breast Cancer Cells. Neoplasia. 2018;20(5):489–98. |
| Riluzole              | ALS           | Glutamate inhibitor                   | - Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat. 2012 Apr;132(2):565–73. |
|                       |               |                                       | - Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM, et al. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. Breast Cancer Res Treat. 2016;157(2):217–28. |
|                       |               |                                       | - Speyer CL, Bukhsh MA, Jafry WS, Sexton RE, Bandypadhayay S, Gorski DH. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer. Breast Cancer Res Treat. 2017 Nov;166(2):407–19. |
| Drug                | Condition          | Mechanism/Action                                                                 |
|---------------------|--------------------|----------------------------------------------------------------------------------|
| Simvastatin         | Hyperlipidemia     | HMGCR inhibitor                                                                   |
|                     |                    | - Kou X, Yang Y, Jiang X, Liu H, Sun F, Wang X, et al. Vorinostat and Simvastatin  |
|                     |                    | have synergistic effects on triple-negative breast cancer cells via abrogating     |
|                     |                    | Rab7 prenylation. Eur J Pharmacol. 2017 Oct 15;813:161–71.                        |
|                     |                    | - Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F,    |
|                     |                    | Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K,  |
|                     |                    | Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents      |
|                     |                    | triple-negative breast cancer metastasis in pre-clinical models through           |
|                     |                    | regulation of FOXO3a. Breast Cancer Res Treat. 2015 Dec;154(3):495-508.           |
|                     |                    | - Kou X, Jiang X, Liu H, Wang X, Sun F, Han J, et al. Simvastatin functions as a   |
|                     |                    | heat shock protein 90 inhibitor against triple-negative breast cancer. Cancer      |
|                     |                    | Sci. 2018 Oct;109(10):3272–84.                                                   |
|                     |                    | - Jung HH, Lee S-H, Kim J-Y, Ahn JS, Park YH, Im Y-H. Statins affect ETS1-over-     |
|                     |                    | expressing triple-negative breast cancer cells by restoring DUSP4 deficiency.      |
|                     |                    | Sci Rep. 2016 08;6:33035                                                          |
|                     |                    | - Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, et al. Dual inhibition     |
|                     |                    | of Wnt and Yes-associated protein signaling retards the growth of triple-          |
|                     |                    | negative breast cancer in both mesenchymal and epithelial states. Mol Oncol.     |
|                     |                    | 2018;12(4):423–40.                                                              |
|                     |                    | - Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu    |
|                     |                    | W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes  |
|                     |                    | differentiated and stem-like breast cancer cell lines and is associated with      |
|                     |                    | improved local control in inflammatory breast cancer patients treated with        |
|                     |                    | postmastectomy radiation. Stem Cells Transl Med. 2014 Jul;3(7):849-56.           |
|                     |                    | - Castellanos-Esparza YC, Wu S, Huang L, Buquet C, Shen R, Sanchez-Gonzalez B,    |
|                     |                    | et al. Synergistic promoting effects of pentoxifylline and simvastatin on the     |
|                     |                    | apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018   |
|                     |                    | Apr;52(4):1246–54.                                                              |
|                     |                    | - Abdoul-Azize S, Buquet C, Li H, Picquenot J-M, Vannier J-P. Integration of Ca2+  |
|                     |                    | signaling regulates the breast tumor cell response to simvastatin and doxorubicin.|
|                     |                    | Oncogene. 2018;37(36):4979–93.                                                   |
| Sodium Bicarbonate  | Relief of wind      |                                                                                  |
|                     | and gripping pains  |                                                                                  |
|                     |                    | - Abumanhal-Masarweh H, Koren L, Zinger A, Yaari Z, Krinsky N, Kaneti G, et al.   |
|                     |                    | Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular    |
|                     |                    | uptake of doxorubicin. J Control Release. 2019 Feb 28:296:1–13.                  |

Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Sulfasalazine | Rheumatoid arthritis; ulcerative colitis; active Crohn’s Disease. | Cyclooxygenase inhibitor |
|---------------|---------------------------------------------------------------|--------------------------|
|               | - Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, et al. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016 Mar 15;7(11):11756–69. |
|               | - Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14;24(4):450–65 |

| Thioridazine | Psychotic disorders | Dopamine receptor antagonist |
|--------------|---------------------|-----------------------------|
|               | - Tegowski M, Fan C, Baldwin AS. Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2. J Biol Chem. 2018 12;293(41):15977–90. |
|               | - Goyette M-A, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, et al. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer. Oncotarget. 2019 Mar 12;10(21):2055–67 |

| Tigecycline | Infections | Bacterial 30S ribosomal subunit inhibitor |
|-------------|------------|----------------------------------------|
|             | - Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016 03;126(10):3739–57 |

| Tocilizumab | Rheumatoid arthritis | |
|------------|---------------------|-------------------|
|            | - Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res. 2018 14;20(1):54. |
|            | - Weng Y-S, Tseng H-Y, Chen Y-A, Shen P-C, Al Haq AT, Chen L-M, et al. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019 18;18(1):42. |

| Trifluoperazine | Psychotic disorders | Dopamine receptor antagonist |
|----------------|---------------------|-----------------------------|
|                | - Goyette M-A, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, et al. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer. Oncotarget. 2019 Mar 12;10(21):2055–67. |
|                | - Feng Z, Xia Y, Gao T, Xu F, Lei Q, Peng C, et al. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing GO/G1 arrest and apoptosis. Cell Death Dis. 2018 Sep 26;9(10):1006. |
|                | - Fancy RM, Kim H, Napier T, Buchsbaum DJ, Zinn KR, Song Y. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem. 2018;119(7):6216–30. |
|                | - Park S-H, Chung YM, Ma J, Yang Q, Berek JS, Hu MC-T. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):42110–25. |
| Drug            | Condition                          | Classification                      | References                                                                                                                                 |
|-----------------|------------------------------------|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Valproic acid   | Epilepsy                           | HDAC inhibitor                       | - Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, et al. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018 Jul 26;9(8):815.<br>- Tarasenko N, Chekroun-Setti H, Nudelman A, Rephaeli A. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. J Cell Biochem. 2018;119(4):3417–28<br>- Prestegui-Martel B, Bermúdez-Lugo JA, Chávez-Blanco A, Dueñas-González A, García-Sánchez JR, Pérez-González OA, et al. N-[2-hydroxyphenyl]-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells. J Enzyme Inhib Med Chem. 2016;31(sup3):140–9<br>- Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, et al. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10;7(19):28329–39<br>- Wiegmans AP, Yap P-Y, Ward A, Lim YC, Khanna KK. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Mol Cancer Ther. 2015 Oct;14(10):2321–31 |
| Verapamil       | Hypertension, angina pectoris      | Calcium channel blocker              | - Deshmukh RR, Kim S, Elghoul Y, Dou QP. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors. J Cell Biochem. 2017;118(5):1239–48 |
| Verteporfin     | Exudative age-related macular degeneration | Photosensitising agent            | - Li Y, Wang S, Wei X, Zhang S, Song Z, Chen X, et al. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance. Cancer Sci. 2019 Feb;110(2):561–7.<br>- Kim J, Shamul JG, Shah SR, Shin A, Lee BJ, Quinones-Hinojosa A, et al. Verteporfin-Loaded Poly(ethylene glycol)-Poly(beta-amino ester)-Poly(ethylene glycol) Triblock Micelles for Cancer Therapy. Biomacromolecules. 2018 13(19):3361–70<br>- Andrade D, Mehta M, Griffith J, Panneerselvam J, Srivastava A, Kim T-D, et al. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget. 2017 Nov 17;8(58):98495–508 |
| Warfarin        | Prophylaxis of systemic embolism, of venous thrombosis and pulmonary embolism. | Vitamin K antagonist                | - Beaudin S, Kokabee L, Welsh J. Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells. Oncotarget. 2019 Mar 19;10(23):2292–305 |
Table S2. Preclinical references for repurposing of drugs for TNBC by ReDO DB. (continued)

| Drug          | Function                                         | Reference                                                                 |
|---------------|--------------------------------------------------|----------------------------------------------------------------------------|
| Zoledronic acid | Osteoporosis, prophylaxis of skeletal fractures and treat hypercalcemia of malignancy, treat pain from bone metastases | Liu H, Wang S-H, Chen S-C, Chen C-Y, Lin T-M. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells. BMC Cancer. 2019 Feb 26;19(1):176.  
Cai X-J, Wang Z, Cao J-W, Ni J-J, Xu Y-Y, Yao J, et al. Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer. Oncotarget. 2017 Oct 13;8(48):84248–57  
Schech AJ, Kazi AA, Gilani RA, Brodie AH. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Mol Cancer Ther. 2013 Jul;12(7):1356–66  
Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, et al. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol. 2013 Apr;42(4):1263–70  
Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, et al. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012 Nov 22;12(1):48.  
Gschwantler-Kaulich D, Weingartshofer S, Grunt TW, Mairhofer M, Tan Y, Gamper J, et al. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLoS ONE. 2017;12(9):e0185566  
Tripathi R, Singh P, Singh A, Chagtoo M, Khan S, Tiwari S, et al. Zoledronate and Molecular Iodine Cause Synergistic Cell Death in Triple Negative Breast Cancer through Endoplasmic Reticulum Stress. Nutr Cancer. 2016 Jun;68(4):679–88. |